| Lucentis (ranibizumab) / Roche, Novartis |
ACTRN12618000079246: The Influence of Serum and Aqueous Cytokine Concentrations on the Efficacy of Intravitreal Ranibizumab for the Treatment of Diabetic Macular Oedema |
|
|
| Not yet recruiting | 4 | 60 | | | The Centre for Eye Research Australia , Juvenile Diabetes Research Foundation | Diabetic Macular Oedema | | | | |
ACTRN12609001051235: Efficacy and safety of verteporfin (Visudyne) in combination with ranibizumab (Lucentis) for the treatment of AMD (Aged-Related Macular Degeneration) (LIV- Lucentis injection with Visudyne). |
|
|
| Recruiting | 4 | 20 | | | Royal Adelaide Hospital, Novartis | AMD (Aged-Related Macular Degeneration) | | | | |
ChiCTR-TRC-14004562: Zhixue Quyu Mingmu Tablet in the Treatment of Ocular Fundus Hemorrhage Age-related Macular Degeneration (Syndrome of Yin Deficiency & Liver Hyperactivity and Heat Injury of Collaterals) |
|
|
| Completed | 4 | 144 | | Subjects were injected ranibizumab once 2 weeks before enrollment. After recruitment, will oral Zhixue Quyu Mingmu Tablet 5 pieces once, three times a day ;placebo of Zhixue Quyu Mingmu Tablet 5 pieces once, three times a day + Ranibizumab injection | Peking Union Medical College Hospital; Level of the institution：, Shanxi Momentum Pharmaceutcal Company | Ocular Fundus Hemorrhage Age-related Macular Degeneration (Syndrome of Yin Deficiency &Liver Hyperactivity and Heat Injury of Collaterals) | | | | |
ChiCTR-IPR-16009191: Clinical Efficacy of Intravitreal Conbercept for the Treatment Macular Edema secondary to Branch Retinal Vein Occlusion |
|
|
| Recruiting | 4 | 60 | | conbercept ;Lucentis | Shangdong Provincial Hospital; Shangdong Provincial Hospital, Shandong Nature Science Foundation | retina branch vein occlusion | | | | |
2013-000133-12: A randomized controlled multicentre study to assess the non-inferiority of the safety of bevacizumab compared to ranibizumab administered by intravitreal injection in patients with macular degeneration or other exudative not age-related macular Studio randomizzato controllato multicentrico per valutare la non-inferiorità della sicurezza di bevacizumab rispetto a ranibizumab somministrati per via intravitreale in pazienti con degenerazione maculare senile o altre maculopatie essudative non correlate all’età |
|
|
| Ongoing | 4 | 1780 | Europe | Concentrate for solution for infusion, Solution for injection, AVASTIN, LUCENTIS | Azienda Ospedaliera Universitaria Integrata Verona, Azienda Ospedaliera Universitaria Integrata Verona | - Age-related macular degeneration - Diabetic retinal oedema - Retinal perivascular sheathing - Choroidal neovascularisation - degenerazione maculare senile essudativa - edema maculare diabetico - edema maculare da occlusione venosa centrale o di branca - neovascolarizzazioni coroideali, - Age-related macular degeneration - Diabetic retinal oedema - Retinal perivascular sheathing - Choroidal neovascularisation - degenerazione maculare senile essudativa - edema maculare diabetico - edema maculare da occlusione venosa centrale o di branca - neovascolarizzazioni coroideali, Diseases [C] - Eye Diseases [C11] | | | | |
2013-005091-17: Variation of choroidal Thickness 15 days after the first ranibizumab intravitreal injection in naïve patients WIth Neovascular age-related macular degeneration: pilot Study. – |
|
|
| Ongoing | 4 | 1 | Europe | RANIBIZUMAB, Solution for injection, LUCENTIS | POLICLINICO GEMELLI, NOVARTIS | Wet age-related macular degeneration, Wet age-related macular degeneration, Body processes [G] - Ocular Physiological Phenomena [G14] | | | | |
ChiCTR-ONC-13003646: Function of ranibizumab intraocular injection in the control of neovascular glaucoma |
|
|
| Completed | 4 | 50 | | intraocular injection | Qilu Hospital of Shandong University; Level of the institution：, the Independent Innovation Foundation to Universities and Colleges by Jinan Science and Technology Bureau | neovascular glaucoma | | | | |
2013-004656-38: Assessment of the suitability of serum VEGF level as diagnostic factor in macula edema under therapy with Lucentis® (ranibizumab) Bewertung der Eignung des Serum VEGF Spiegels als diagnostischer Faktor bei einem Makulaödem unter Therapie mit Lucentis® (Ranibizumab) |
|
|
| Ongoing | 4 | 30 | Europe | Injection, Lucentis Injektionslösung | Prof. Dr. Karl-Heinz Emmerich, Novartis Pharma GmbH | Central retinal vein occlusionRetinal vein occlusion, Occlusion of a vein of the retina, Diseases [C] - Eye Diseases [C11] | | | | |
2014-002790-11: Evaluation of additional peripheral panretinal LASER-treatment on recurrences of macular edema due to CRVO undergoing anti-VEGF treatment with ranibizumab Evaluierung eines „Treat-and-Extend“ Schemas bei Patienten mit retinalem Venenverschluss mit und ohne Laserphotokoagulation von ischämischen Netzhautarealen |
|
|
| Ongoing | 4 | 60 | Europe | Solution for injection, Lucentis | Ludwig-Maximilians Universität München, Novartis | Makulaödem nach retinalem Venenverschluss (CRVO), Auftreten einer Schwellung (Ödem) der Netzhaut nach dem Verschluss des ableitenden Gefäßes und nachfolgender Flüssigkeitsansammlung im Gewebe des Auges, Diseases [C] - Eye Diseases [C11] | | | | |
2014-005700-24: Cytokine Levels within patients with diabetic macular edema. |
|
|
| Ongoing | 4 | 20 | Europe | Lucentis, Ozurdex, EMEA/H/C/000715, EU/1/10/638/001, Injection, Intravitreal implant in applicator, Lucentis, Ozurdex | Abteilung für Augenheilkunde, AKH Linz, Bayer | Diabetic Retinopathy and diabetic macular edema are leading causes for visual loss and blindness in young adults around the world., Diabetic Macular Edema, Diseases [C] - Eye Diseases [C11] | | | | |
| Ongoing | 4 | 610 | Europe | NA, NA, Solution for injection, Avastin, Lucentis | Belfast Health and Social Care Trust, NIHR HTA | Neovascular age-related macular degeneration, Blindness, Diseases [C] - Eye Diseases [C11] | | | | |
2006-002977-33: Safety and efficacy of intravitreal injections of ranibizumab/Lucentis in combination with verteporfin photodynamic therapy (PDT) in patients with choroidal neovascularisation (CNV) secondary to age related macular degeneration |
|
|
| Ongoing | 4 | 10 | Europe | ranibizumab, Visudyne (verteporfin), RFB002, BPD952, Visudyne (verteporfin), Visudyne (verteporfin) | University Eye Hospital | Age related macular degeneration (AMD) is the leading cause of blindness in individuals older than 50 years in the developed world. Eighty to ninety percent of rapid and severe vision loss due to AMD is attributable to the so called »wet form« characterized by newly formed blood vessels from choroidea (choroidal neovascularization, CNV). These blood vessels permeate blood and fluid, causing fibrosation of macula and degeneration of photoreceptors. | | | | |
2006-004292-35: A pillot study to examine the safety and efficacy of intravitreal ranubizimab/dexamethasone administration and oral minocycline in addition to Visudyne (verteporfin) photdynamic therapy for subfoveal choroidal neovascularization secondary to age related macular degeneration degeneration: an open label trial. |
|
|
| Ongoing | 4 | 20 | Europe | Dexamethasone, Ranubizimab, Verteporfin, Dexamethasone, Lucentis, Visudyne, Acnamino MR, Dexamethasone, Lucentis, Visudyne, Acnamino MR | Kings College Hospital NHS Foundation Trust | Age related macular degeneration | | | | |
2007-004487-53: Pilot study of association of VEGF polymorphisms with clinical efficacy and tolerability of therapy in patients affected by exudative (neovascular) age-related macular degeneration. |
|
|
| Ongoing | 4 | 300 | Europe | MACUGEN*INIET 1 SIR 0,3MG, LUCENTIS*INIET 1FL 0,3ML 10MG/, MACUGEN*INIET 1 SIR 0,3MG, LUCENTIS*INIET 1FL 0,3ML 10MG/ | AZIENDA OSPEDALIERA PISANA | Exudative and atrophic age-related macular degeneration. | | | | |
2008-000544-13: Estudio sobre la eficacia y la seguridad del tratamiento combinado con ranibizumab (Lucentis®) y terapia fotodinámica con verteporfin (Visudyne®) versus monoterapia con ranibizumab (Lucentis®) en la Neovascularización Coroidea (NVC) secundaria a Miopía Patológica. |
|
|
| Ongoing | 4 | 20 | Europe | Lucentis, Visudyne, Lucentis, Visudyne | Departamento de Oftalmología. Hospital Clínico San Carlos | Pacientes con neovascularización coroidea secundaria a miopía magna | | | | |
2006-004367-57: Treatment of retinal angiomatous proliferation lesions due to age-related macular degeneration with ranibizumab (Lucentis®) and photodynamic therapy with verteporfin (Visudyne®) |
|
|
| Ongoing | 4 | 15 | Europe | Lucentis, Lucentis, Visudyne, Lucentis, Visudyne | Department of Ophthalmology, Medical University of Graz | Subtype of neovascular age-related macular degeneration, so called retinal angiomatous proliferation or RAP. | | | | |
2010-018673-37: The use of Ranibizumab (Lucentis ®) for the treatment of corneal neovascularisation |
|
|
| Ongoing | 4 | 20 | Europe | Ranibizumab(Lucentis®), Lucentis®, Lucentis® | University of Nottingham | Corneal neovessels | | | | |
2010-021777-37: \"A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month\" |
|
|
| Ongoing | 4 | 20 | Europe | Lucentis, Lucentis 10 mg/ml Injektionslösung, Lucentis 10 mg/ml Injektionslösung | Universitätsklinikum Schleswig-Holstein (UK-SH) | Retinal function in patients with wet age-related macular degeneration | | | | |
2011-004613-17: The effect of Lucentis (ranibizumab) on retinal function in diabetic patients with visual impairment and diabetic svelling of the makula Effekt av Lucentis ( ranibizumab), givet i glaskroppen i ögat, på näthinnans funktion hos diabetiker med synnedsättning och svullnad i gula fläcken |
|
|
| Ongoing | 4 | 20 | Europe | LUCENTIS, LUCENTIS (ranibizumab), LUCENTIS (ranibizumab) | Inst of Ophtalmology Lund University hospital, Novartis Sverige AB | Diabetic makula edema with visual impairment Diabetes makula ödem med synnedsättning | | | | |
2012-003431-37: Ensayo clínico en fase IV, abierto, aleatorizado, de 2 brazos, multicéntrico y de 12 meses de duración, para evaluar la eficacia y seguridad de un régimen PRN flexible individualizado de \"esperar y extender\" versus un régimen PRN según criterios de estabilización mediante evaluaciones mensuales de inyecciones intravítreas de ranibizumab 0,5 mg en pacientes naive con neovascularización coroidea secundaria a la degeneración macular relacionada con la edad. Ensayo clínico en fase IV, abierto, aleatorizado, de 2 brazos, multicéntrico y de 12 meses de duración, para evaluar la eficacia y seguridad de un régimen PRN flexible individualizado de \"esperar y extender\" versus un régimen PRN según criterios de estabilización mediante evaluaciones mensuales de inyecciones intravítreas de ranibizumab 0,5 mg en pacientes naive con neovascularización coroidea secundaria a la degeneración macular relacionada con la edad. |
|
|
| Ongoing | 4 | 166 | Europe | LUCENTIS 10mg/ml solución inyectable, LUCENTIS 10mg/ml solución inyectable | Sociedad Española de retina y Vítreo, Novartis Farmacéutica S.A | pacientes naive con degeneración macular relacionada conla edad pacientes naive con degeneración macular relacionada conla edad | | | | |
ChiCTR1900021656: Therapeutic Effects of Ranibizumab in Patients with Polypoidal Choroidal Vasculopathy |
|
|
| Completed | 4 | 80 | | Intravitreal Ranibizumab injection | Ophthalmology Department of Beijing Hospital; Beijing Hospital, None | polypoidal choroidal vasculopathy | | | | |
ChiCTR1800014289: A randomized, double blind, controlled trials for assessing the efficacy of 0.5 mg ranibizumab only in subject with macular laser combined due to diabetic branch retinal vein occlusion |
|
|
| Recruiting | 4 | 80 | | razorumab combined with macular laser photocoagulation ;razorumab alone | Beijing Hospital; Beijing Hospital, Beijing Hospital | Branch vein occlusion macular edema | | | | |
ChiCTR-OIC-16009509: Clinical study of intravitreal ranibizumab as early treatment for macular edema result by retinal vein occlusion |
|
|
| Not yet recruiting | 4 | 100 | | intravitreal ranibizumab | The Second Xiangya Hospital of Central South University; Department of Ophthalmology of The Second Xiangya Hospital, Central South University, raise independently | retinal vein occlusion | | | | |
ChiCTR-IPR-15006695: Adjunctive with intravitreal injection of ranibizumab before Ahmed glaucoma valve implantation in the treatment of neovascular glaucoma: a prospective randomized controlled study |
|
|
| Suspended | 4 | 92 | | adjunctive intravitreal ranibizumab injection with Ahmed Glaucoma Valve implantation ;adjunctive intravitreal bevacizumab injection with Ahmed Glaucoma Valve implantation | Shanghai First People's Hospital; Shanghai First People's Hospital, Shanghai Science and Technology Innovation action medical key Program (1341195400) | neovascular glaucoma | | | | |
ChiCTR-IPR-17010568: The Randomized Double-blind Controlled Clinical Trial of Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for Macular Edema Secondary to Branch Retinal Vein Occlusion |
|
|
| Recruiting | 4 | 64 | | macular laser ;no | Beijing Hospital; Beijing Hospital, Beijing Hospital | Branch retinal vein occlusion | | | | |
2019-003133-42: Treatment of neovascular AMD: Artificial intelligence in real-world setting |
|
|
| Not yet recruiting | 4 | 290 | Europe | Lucentis, Eylea, Beovu, EMEA/H/C/000715, EMEA/H/C/002392, EMEA/H/C/004913, Solution for injection, Lucentis, Eylea, Beovu | Medical University of Vienna, Department of Ophthalmology and Optometry, MUW, Department of Ophthalmology and Optometry | Nevoascular age related macular degneration (nAMD), wet macular degeneration, Diseases [C] - Eye Diseases [C11] | | | | |
ChiCTR-OPC-17013023: Conbercept vs Ranibizumab for patients with age-related macular degeneration: a prospective cohort study |
|
|
| Not yet recruiting | 4 | 300 | | Conbercept ;Ranibizumab | Guizhou Provincial People's Hospital; Guizhou Provincial People's Hospital, Independently | Age-related macular degeneration | | | | |
ChiCTR2000038086: A prospective randomized controlled trial for comparing 1+prn and 3+prn regimen in the treatment of macular edema secondary to branch retinal vein occlusion |
|
|
| Recruiting | 4 | 72 | | Patients were treated with one injection of intravitreal ranibizumab (IVR) and further IVR injections were administered as needed. ;Patients were treated with three consecutive monthly injections of IVR and further IVR injections were administered as needed. | Eye & ENT Hospital of Fudan University; EYE & ENT hospital of FUDAN UNIVERSITY, Beijing Novartis Pharma Co., Ltd. | branch retinal vein occlusion | | | | |
ChiCTR2000031400: Evaluate the effect of anti VEGF injection on postoperative vitreous rebleeding during perioperative period of proliferative diabetic retinopathy |
|
|
| Recruiting | 4 | 86 | | Ranibizumab ;none | Shanxi Eye Hospital; Shanxi Eye Hospital, Key Research and Development (R&D) Projects of Shanxi Province (201803D31184) | Diabetic Retinopathy | | | | |
NCT03999125: Anti-VEGF Therapy Versus Dexamethasone Implant for DME |
|
|
| Not yet recruiting | 4 | 150 | Europe | Aflibercept,, Ranibizumab, Dexamethasone Implant, Laser, Ranibizumab Injection, Dexamethasone Implant, Aflibercept, Laser, Ozurdex Drug Implant Product | Sudhalkar Eye Hospital | Clinically Significant Macular Edema Due to Diabetes Mellitus | 06/21 | 06/23 | | |
ChiCTR2300067476: Study on the Effect of Different anti-VEGF drugs on Fibrovascular Membrane of Proliferative Diabetic Retinopathy |
|
|
| Completed | 4 | 24 | | Ranibizumab ;Conbercept ;Aflibercept | Tianjin Medical University Eye Hospital; Tianjin Medical University Eye Hospital, Self-financing | diabetic retinopathy | | | | |
NCT03709745: Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion |
|
|
| Completed | 4 | 110 | Europe | Aflibercept Injection [Eylea], Eylea, Ranibizumab Injection [Lucentis], Lucentis | St. Erik Eye Hospital | Branch Retinal Vein Occlusion with Macular Edema | 10/21 | 07/22 | | |
NCT04464694: Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema |
|
|
| Not yet recruiting | 4 | 142 | RoW | Ranibizumab, Lucentis, Sham injection, Pars plana vitrectomy, Vitrectomy | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Novartis | Proliferative Diabetic Retinopathy, Diabetic Macular Edema | 12/21 | 06/22 | | |
ChiCTR2000037469: The efficacy of arbazepril and ranibizumab in the treatment of retinopathy of prematurity - A prospective randomized controlled trial |
|
|
| Not yet recruiting | 4 | 80 | | intravitreal injection of aflibercept ;intravitreal injection of ranibizumab | Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine; Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai Hospital Development Center | retinopathy of prematurity | | | | |
NCT05282420: Ranibizumab Versus Aflibercept for CRVO in Young Patients. |
|
|
| Recruiting | 4 | 40 | RoW | intravitreal injection of Ranibizumab, intravitreal injection of Aflipercept, Ranibizumab, Aflibercept | Qena Faculty of medicine, South Valley University | Non-Ischemic Central Retinal Vein Occlusion With Macular Edema | 04/22 | 05/22 | | |
| Recruiting | 4 | 2323 | | Ranibizumab | Zhongshan Ophthalmic Center, Sun Yat-sen University; Zhongshan Ophthalmic Center, Novartis Beijing | Age-Related Macular Degeneration/Diabetic Macular Edema/Macular Edema secondary to Retinal Vein Occlusion | | | | |
STAMP, NCT03832179: Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification |
|
|
| Recruiting | 4 | 32 | US | Bevacizumab, Avastin, Ranibizumab, Lucentis, Aflibercept, Eylea, Ozurdex, Dexamethasone implant | Bay Area Retina Associates, Allergan | Diabetic Macular Edema, Cataract | 07/22 | 10/22 | | |
ChiCTR2000035032: Efficacy of different doses of anti-VEGF with vitrectomy in the treatment of proliferative diabetic retinopathy |
|
|
| Recruiting | 4 | 100 | | 0.5mg ranibizumab injection after PPV ;1.0mg ranibizumab injection after PPV | Shanghai General Hospital; Shanghai General Hospital, Social donation | proliferative diabetic retinopathy | | | | |
REBEL, NCT04991350: Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema |
|
|
| Terminated | 4 | 5 | RoW | Intravitreal ranibizumab, Lucentis, Intravitreal bevacizumab, Avastin | Cairo University | Diabetic Macular Edema, Macular Ischemia, Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression | 09/22 | 11/22 | | |
JQMMT+RA, NCT06234514: Manage Macular Cystoid Edema with Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab |
|
|
| Recruiting | 4 | 100 | RoW | Jueling Mingmu decoction, intravitreal injections of 0.5mg ranibizumab, 0.5mg ranibizumab | Dongyang People's Hospital | Macular Cystoid Edema | 03/25 | 05/25 | | |
ChiCTR2100043531: A Clinical study of decreasing the number of injections of Ranibizumab in diabetic macular edema by using doxium |
|
|
| Recruiting | 4 | 72 | | calcium dobesilate (doxium） ;placebo | The First Affiliated Hospital of Jinan University; The First Affiliated Hospital of Jinan University, Bethune Charitable Foundation | Diabetic macular edema | | | | |
NCT05386160: Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy |
|
|
| Recruiting | 4 | 96 | RoW | Ranibizumab Injection [Lucentis], Phacoemulsification | Ruijin Hospital | Mild Non-proliferative Diabetic Retinopathy, Cataract Diabetic, Diabetic Retinopathy | 03/23 | 03/23 | | |
ChiCTR2200057703: A multicenter, single arm clinical trial of intravitreal injection of Aflibercept in patients with neovascular age-related macular degeneration complicated with type I choroidal neovascularization with low response to ranibizumab or Conbercept |
|
|
| Not yet recruiting | 4 | 30 | | Injection of Aflibercept | West China Hospital of Sichuan University; West China Hospital of Sichuan University, Bayer Medical Healthcare Co., LTD. | Neovascular age-related macular degeneration (nAMD) | | | | |
ACTRN12615001094561: The combination treatment of laser bypass (chorioretinal venous anastomosis) and Lucentis for the treatment of macula oedema (swelling at the back of the eye) that has occurred as a result of a central retinal vein occlusion, compared to the published results of Lucentis treatment only. |
|
|
| Active, not recruiting | 4 | 100 | | | Lions Eye Institute, Lions Eye Institute | Maucula oedema secondary to central retinal vein occlusion. | | | | |
ChiCTR2000030434: Intervention study of intravitreal injection of ranibizumab in the treatment of diabetic retinopathy |
|
|
| Recruiting | 4 | 30 | | Intravitreal injection of thunderzumab | School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University; School of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University, No | diabetic retinopathy | | | | |
Belvedere, NCT04853251: A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration(nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) |
|
|
| Recruiting | 4 | 188 | US | SUSVIMO PDS Implant, LUCENTIS (ranibizumab injection) | Genentech, Inc. | Neovascular Age-related Macular Degeneration | 04/27 | 04/27 | | |
| Recruiting | 4 | 168 | Canada | Intravitreal ranibizumab | Unity Health Toronto | Age Related Macular Degeneration, Diabetic Macular Edema, Macular Edema, Retinal Vein Occlusion | 02/24 | 02/24 | | |
NCT05861466: Comparative Study Between IVI of Ranibizumab with and Without Prior ACP in Patients with DME Using OCT-A |
|
|
| Completed | 4 | 102 | RoW | intra-vitreal injection of Ranibizumab, anterior chamber paracentesis | Ain Shams University | Diabetic Macular Edema | 11/24 | 11/24 | | |
NCT06708624: Ocular Safety and Usability Study for FYB201 PFS |
|
|
| Completed | 4 | 31 | US | FYB201 0.5 mg (0.05 mL of 10 mg/mL), ranibizumab-eqrn | Formycon AG | Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema | 08/24 | 08/24 | | |
NCT04075136: Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy |
|
|
| Withdrawn | 4 | 150 | US | Ranibizumab, Lucentis, Photodynamic laser treatment (PDT), Triamcinolone Acetonide, Triesence, verteporfin, Visudyne | Wake Forest University Health Sciences, Modulight | Exudative Age Related Macular Degeneration | 11/24 | 12/24 | | |
NCT02321267: Cohort Study of the Clinical Course of Macular Diseases in Kagawa |
|
|
| Recruiting | 4 | 1000 | Japan | ranibizumab, aflibercept, pegaptanib, verteporphin, Lucentis, Eylea, Macugen, Vizudyne | Kagawa University | Macular Disease | 12/24 | 12/24 | | |
ACTRN12613001020774: To investigate the role of Intravitreal Aflibercept (Eylea) in the treatment of patients whose wet Age related Macular degeneration is not adequately controlled with conventional anti VEGF (intravitreal Avastin or Lucentis) treatment. |
|
|
| Not yet recruiting | 3/4 | 50 | | | Greenlane Clinical Centre Auckland District Health Board, Auckland District Health Board | Exudative (Wet) Age related Macular Degeneration | | | | |
ACTRN12614000511639: Prophylactic Ranibizumab in the fellow eye in patients with wet type Age Related Macular Degeneration |
|
|
| Not yet recruiting | 3/4 | 134 | | | El Gawhara eye center ,Egypt, El Gawhara eye center ,Egypt | Wet Age Related Macular Degeneration (AMD) | | | | |
2006-004978-27: Initial Combination of Photodynamic Therapy with Verteporfin and Intravitreal Administration of Ranibizumab in Patients with Subfoveal Choroidal Neovascularisation due to Age-related Macular Degeneration |
|
|
| Ongoing | 3/4 | 15 | Europe | will be send separatly by Novartis Pharma | Zentralklinikum St. Pölten | The case-series is designed to evaluate the safety and efficacy of intravitreal ranibizumab used in combination with verteporfin photodynamic therapy (Visudyne) for the treatment of subfoveal CNV secondary to AMD | | | | |
2013-000031-27: Injections into the eye (drug Lucentis) in diabetic patients in whom no further treatment is currently available in clinic when they have developed swelling of the centre of the macula associated with lack of blood supply. |
|
|
| Ongoing | 3/4 | 80 | Europe | Lucentis, Lucentis, Lucentis | Moorfields Eye Hospital, Fight for Sight, Novartis Pharmaceuticals UK Ltd | Ischaemic Diabetic Macular Oedema | | | | |
ACTRN12614000497606: The RAAMP study. Ranibizumab versus aflibercept for age-related macular degeneration, using multifocal objective pupil perimetry. |
|
|
| Recruiting | 3 | 60 | | | Australian National University (ANU), NHMRC | wet age related macular degeneration (AMD) | | | | |
2006-003976-36: An academic monocenter study assessing the safety and efficacy of Lucentis (ranizumab 0.3 mg) administered in conjunction with photodynamic therapy with Visudyne in patients with occult or predominantly classic subfoveal choroidal neovascularization secondary to age-related macular degeneration. |
|
|
| Ongoing | 3 | | Europe | Lucentis, Visudyne, RFB002, BPD952, Solution for injection, Powder for solution for infusion, Visudyne | Professor Anita Leys - Dienst Oftalmologie UZ St. Rafaël | Male and female patients ≥50 years of age with subfoveal choroidal neovascularisation lesions secondary to age related macular degeneration, either predominantly classic or occult with no classic component. | | | | |
2010-023923-78: “ A prospective clinical trial to evaluate the V4 Drug delivery device for long term delivery of Ranibizumab for the Treatment of Choroidal Neovascularization” |
|
|
| Ongoing | 3 | 20 | Europe | Solution for injection, Lucentis | Forsight Vision 4, Inc. | Choroidal Neovascularization (CNV) secondary to Age-related Macular Degeneration (AMD) is among the leading causes of blindness in the world. The primary treatment modality is injection of Lucentis into the vitreous. Such treatment maintains baseline vision in ~90% of patients and improves vision in ~40% of patients and has thus become the first treatment of choice for this disease. | | | | |
| Active, not recruiting | 3 | 240 | Canada, Europe, RoW | ranibizumab | Novartis Pharmaceuticals, Genentech | Diabetic Macular Edema, Visual Impairment | 02/12 | 02/12 | | |
2014-000272-26: A Multicentre Phase III Double-masked Randomised Controlled Non-Inferiority Trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for Macular Oedema (MO) due to Central Retinal Vein Occlusion (CRVO). |
|
|
| Ongoing | 3 | 459 | Europe | Aflibercept, Bevacizumab, Lucentis, EMA/CHMP/299413/2012, EU/1/04/300/001, Solution for injection, Concentrate for solution for injection, Eylea, Avastin, Lucentis | Moorfields Eye Hospital NHS Foundation Trust, NIHR HTA CET | Macular Oedema due to Central Retinal Vein Occlusion (CRVO)., Swelling of the centre of the retina, the light detecting layer at the back of the eye, due to blockage of a blood vessel that usually drains blood out of this layer., Diseases [C] - Eye Diseases [C11] | | | | |
2006-005468-25: A randomized study comparing the safety and efficacy of ranibizumab (Lucentis ®) to sham in patients with macular edema secondary to central retinal vein occlusion (CRVO). |
|
|
| Ongoing | 3 | 32 | Europe | Lucentis, RFB002, | Retinaklinikken Aleris | Macular edema secondary to central retinal vein occlusion (CRVO) | | | | |
2009-013062-11: BEVACIZUMAB COMBINED WITH PDT, VERSUS RANIBIZUMAB AND PEGAPTANIB BOTH COMBINED WITH PDT FOR NEOVACULAR AGE RELATED MACULAR DEGENERATION CLINICAL TRIAL |
|
|
| Ongoing | 3 | 150 | Europe | AVASTIN, MACUGEN, LUCENTIS, VISUDYNE, AVASTIN, MACUGEN, LUCENTIS, VISUDYNE | AZIENDA USL 8 AREZZO | Neovascular Age Related Macular Degeneration | | | | |
2006-005450-71: INTRAVITREAL RANIBIZUMAB THERAPY FOR MACULA EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION (RAVO) |
|
|
| Ongoing | 3 | 60 | Europe | Lucentis, RFB002, Lucentis, Lucentis | Augenklinik der LMU München | Macula edema resulting from central retinal vein occlusion in the eye | | | | |
2007-006093-28: ENSAYO CLÍNICO, ALEATORIZADO, CONTROLADO DOBLE CIEGO, MULTICÉNTRICO PARA EVALUAR LA EFICACIA Y SEGURIDAD DEL BEVACIZUMAB (AVASTIN, Genentech, Inc.) VS RANIBIZUMAB (LUCENTIS, Genentech, Inc.) INTRAVÍTREOS EN LA DEGENERACIÓN MACULAR ASOCIADA A LA EDAD |
|
|
| Ongoing | 3 | 270 | Europe | Avastin®, Lucentis®, Avastin®, Lucentis® | Fundación de Investigación Biomédica Hospital de Getafe | Degeneración macular asociada a la edad tipo exudativo | | | | |
| Ongoing | 3 | 600 | Europe | Lucentis, Avastin, Lucentis, Avastin | Hospices Civils de Lyon | Dégénérescence Maculaire Liée à l’Age (DMLA) | | | | |
2008-007476-19: A prospective case series of Ranibizumab for the treatment of inflammatory and idiopathic choroidal neovascular membranes. |
|
|
| Ongoing | 3 | 15 | Europe | Ranibizumab, | University Hospitals Bristol NHS Trust | idiopathic and inflammatory choroidal neovascular membranes | | | | |
2009-017782-30: Treatment of macular edema due to central retinal vein occlusion with ranibizumab (Lucentis®). |
|
|
| Ongoing | 3 | 20 | Europe | not applicable, Lucentis 10 mg/ml Injektionslösung, Lucentis 10 mg/ml Injektionslösung | Medizinische Universität Graz, Universitäts-Augenklinik | This case-series is designed to evaluate the safety and efficacy of intravitreal ranibizumab (Lucentis®) in the treatment of macular edema due to central retinal vein occlusion. | | | | |
2010-022473-33: Short term effect of Lucentis® (Ranibizumab) as pretreatment to laser photocoagulation versus Lucentis® (Ranibizumab) combined with laser photocoagulation in the treatment of diabetic macular edema. A prospective, randomized study. |
|
|
| Ongoing | 3 | 64 | Europe | Lucentis 10 mg/ml, Lucentis 10 mg/ml | Department of Ophthalmology, Hietzing Hospital | Patients with macular edema due to diabetic retinopathy | | | | |
2012-001006-24: Ranibizumab and Vitrectomy in the Therapy of Diabetic Macular Edema (The RAVIT-DME-Trial) |
|
|
| Ongoing | 3 | 110 | Europe | Lucentis, Lucentis, Lucentis | , Augenklinik Universitaetsallee, , Novartis Pharma | therapy of diabetic macular edema | | | | |
2017-003243-37: Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial |
|
|
| Not yet recruiting | 3 | 240 | Europe | Lucentis, Ozurdex, Methotrexate, EU/1/06/374/001, Injection, Intravitreal implant in applicator, Lucentis, Ozurdex, Methotrexate | MUST Coordinating Centre, John Hopkins Bloomberg School of Public Health | Uveitic macular oedema, Swelling of part of the retina called the macula, which is responsible for fine vision, occuring due to inflammation in the eye (uveitis), Diseases [C] - Eye Diseases [C11] | | | | |
2018-004486-13: A Multicenter Study to Compare Efficacy and Safety of QL1205 Versus Lucentis® in Patients With Wet-AMD. |
|
|
| Ongoing | 3 | 656 | Europe | Lucentis®, QL1205-Qilu ranibizumab biosimilar, QL1205, Solution for injection, Lucentis® | Qilu Pharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd. | Subjects With Wet (neovascular) Age-related Macular Degeneration (wAMD), aged ≥50 years, wet Age-related Macular Degeneration , resulting from damage to the macula, the central portion of the retina caused by the growth of leaky, abnormal blood vessels (choroidal neovascularization), Diseases [C] - Eye Diseases [C11] | | | | |
2020-000681-42: Long-term need of the drug ranibizumab applied as injection into the eye with or without early targeted peripheral laser photocoagulation of the retina for treatment of macular edema due to central retinal vein occlusion Langzeitbedarf des Medikaments Ranibizumab als Injektion ins Auge mit oder ohne frühzeitige gezielte periphere Laser-Photokoagulation der Netzhaut zur Behandlung des Makulaödems infolge eines Zentralvenenverschlusses |
|
|
| Not yet recruiting | 3 | 110 | Europe | Ranibizumab, Injection, Lucentis | Justus-Liebig University Gießen, BMBF | Macular edema due to central retinal vein occlusion Makulaödem infolge eines Zentralvenenverschlusses, Macular edema due to central retinal vein occlusion Makulaödem infolge eines Zentralvenenverschlusses der Netzhaut, Diseases [C] - Eye Diseases [C11] | | | | |
| Active, not recruiting | 3 | 411 | Europe | Stereotactic radiotherapy (16 Gray or Sham), 0.5 mg ranibizumab, Lucentis® | King's College Hospital NHS Trust, King's College London | Neovascular (Wet) Age-related Macular Degeneration (AMD) | 12/21 | 06/24 | | |
2019-003204-12: Pharmacogenomics of antiVEGF in patients with Age-Associated Macular Degeneration. FArmacogenómica de los antiVEGF en pacientes con Degeneración Macular Asociada a la Edad. |
|
|
| Not yet recruiting | 3 | 630 | Europe | AVASTIN 25 MG/ML, Lucentis, 106374003, Concentrate for solution for injection/infusion, Solution for injection, Avastin, Lucentis | Consorcio PSMAR, EU Next Generation | age-related macular degeneration Degeneración macular asociada a la edad, age-related macular degeneration Degeneración macular asociada a la edad, Diseases [C] - Eye Diseases [C11] | | | | |
2021-001970-41: Clinical study to compare efficacy and safety of Intas Ranibizumab with Lucentis. Klinická studie k porovnání účinnosti a bezpečnosti ranibizumabu Intas s přípravkem Lucentis. |
|
|
| Ongoing | 3 | 546 | RoW, Europe | Intas Ranizumab, INTP18, Solution for injection in vial, Solution for injection in pre-filled syringe, Lucentis | Intas Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd. | Neovascular (Wet) Age-Related Macular Degeneration (AMD), Age-related macular degeneration (AMD) is a progressive neurodegenerative disease and a leading cause of visual loss in elderly patients, Diseases [C] - Eye Diseases [C11] | | | | |
| Completed | 3 | 180 | Europe, Japan, US, RoW | Ranibizumab | Novartis Pharmaceuticals | Retinopathy of Prematurity (ROP) | 04/22 | 04/22 | | |
|
NCT05033106: Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity |
|
|
| Recruiting | 3 | 36 | RoW | Bevacizumab, Ranibizumab, avastin, leucentis | Zagazig University, Cairo University | Retinopathy of Prematurity Both Eyes | 09/22 | 09/22 | | |
Pagoda, NCT04108156: A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Subtudy to Evaluate the Safety of Re-Implanting the PDS With Ranibizumab in Participants With DME |
|
|
| Recruiting | 3 | 634 | US | PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Ranibizumab refill exchange | Hoffmann-La Roche | Diabetic Macular Edema | 11/26 | 11/26 | | |
|
| Completed | 3 | 600 | RoW | Lucentis (ranibizumab), LUBT010 (proposed ranibizumab biosimilar) | Lupin Ltd. | Neovascular Age-related Macular Degeneration | 05/24 | 05/24 | | |
PAVILION, NCT04503551: A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm |
|
|
| Active, not recruiting | 3 | 174 | US | PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection | Hoffmann-La Roche | Diabetic Retinopathy | 10/22 | 06/25 | | |
|
2021-000590-93: A study investigating the efficacy, safety, pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis in adults patients with Wet (Neovascular) Age-Related Macular Degeneration |
|
|
| Not yet recruiting | 3 | 550 | Europe | BP05, Lucentis, BP05, Solution for injection, Lucentis | CuraTeQ Biologics Private Ltd., CuraTeQ Biologics Private Ltd. | Wet (Neovascular) Age-Related Macular Degeneration Vlhká (neovaskulárna) vekom podmienená degenerácia makuly, Wet (Neovascular) Age-Related Macular Degeneration Vlhká (neovaskulárna) vekom podmienená degenerácia makuly, Diseases [C] - Eye Diseases [C11] | | | | |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
| Active, not recruiting | 3 | 990 | Europe, Canada, US, RoW | 2.0 mg OPT-302, 0.5 mg ranibizumab, Sham | Opthea Limited | Neovascular Age-related Macular Degeneration | 07/25 | 07/26 | | |
NCT05138029: Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation |
|
|
| Recruiting | 3 | 60 | RoW | Ranibizumab Injection [Lucentis], Lucentis, Inner limiting membrane stripping, Dexamethasone intravitreal implant, Dexamethasone Implants | Affiliated Hospital of Nantong University | Diabetic Retinopathy | 12/23 | 05/24 | | |
| Recruiting | 3 | 442 | RoW | Bevacizumab, Lucentis® | Laboratorios Sophia S.A de C.V. | Diabetic Macular Edema | 08/25 | 08/25 | | |
NORSE EIGHT, NCT06190093: A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD) |
|
|
| Completed | 3 | 400 | US | bevacizumab, ONS-5010, ranibizumab | Outlook Therapeutics, Inc. | Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration | 11/24 | 12/24 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
POYANG, NCT06176352: A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia |
|
|
| Recruiting | 3 | 280 | Europe, RoW | Faricimab, VABYSMO®, faricimab-svoa, RO6867461, RG7716, Ranibizumab, Lucentis, Sham Procedure | Hoffmann-La Roche | Choroidal Neovascularization Secondary to Pathologic Myopia | 08/25 | 04/26 | | |
NCT06305416: A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema |
|
|
| Recruiting | 3 | 70 | RoW | Ranibizumab 10mg/ml Injection, Test Product, Lucentis, Reference Product | Incepta Pharmaceuticals Ltd, Institute for Developing Science and Health Initiatives, Bangladesh | Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Macular Degeneration, Retinal Disease, Retinal Degeneration | 07/25 | 09/25 | | |
NCT05439629: Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | BAT5906 injection, Lucentis | Bio-Thera Solutions | Neovascular (Wet) Age-related Macular Degeneration | 04/24 | 06/25 | | |
NAP, NCT04667039: Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis® |
|
|
| Recruiting | 3 | 408 | RoW | GNR-067, Ranibizumab, Lucentis® | AO GENERIUM | Age Related Macular Degeneration (ARMD) | 08/24 | 09/24 | | |
| Completed | 3 | 410 | Europe, US, RoW | HLX04-O, ranibizumab | Shanghai Henlius Biotech | Age Related Macular Degeneration | 12/24 | 12/24 | | |
| Not yet recruiting | 3 | 250 | NA | Susvimo PDS Implant, RO4893594, Ranibizumab | Hoffmann-La Roche, Genentech, Inc. | Neovascular Age-related Macular Degeneration | 07/28 | 08/28 | | |
| Recruiting | 3 | 110 | Europe | Ranibizumab Injection, Lucentis, Laser photocoagulation | University of Giessen, University of Leipzig | Central Retinal Vein Occlusion With Macular Edema | 07/25 | 07/25 | | |
NCT05480293: This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD |
|
|
| Recruiting | 3 | 446 | RoW | Ranibizumab, SCT510A | Sinocelltech Ltd. | Wet Age-related Macular Degeneration | 07/25 | 08/25 | | |
NCT05520177: A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss |
|
|
| Recruiting | 3 | 350 | RoW | 601 1.25mg, 601, ranibizumab 0.5mg, Lucentis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Branch Retinal Vein Occlusion | 12/25 | 12/25 | | |
ChiCTR2300069823: Therapeutics and Pharmacogenetics of Brolucizumab and Other Anti-VEGF Agents in Treating Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy – Deep Learning towards Precision Medicine |
|
|
| Not yet recruiting | 3 | 864 | | 3 Beovu loading doses, BCVA and SDOCT exam every 4-6 week starting from week 12, further injection as clinically needed ;3 Eylea loading doses, BCVA and SDOCT exam every 4-6 week starting from week 12, further injection as clinically needed ;3 Lucentis loading doses, BCVA and SDOCT exam every 4-6 week starting from week 12, further injection as clinically needed ;3 Beovu loading doses, BCVA and SDOCT exam every 4-6 week starting from week 12, further injection as clinically needed ;3 Eylea loading doses, BCVA and SDOCT exam every 4-6 week starting from week 12, further injection as clinically needed ;3 Lucentis loading doses, BCVA and SDOCT exam every 4-6 week starting from week 12, further injection as clinically needed ;3 loading doses of Eylea or Lucentis as clinically indicated every 1 month; BCVA and SDOCT exam 4-6 weeks after the third injection ;3 loading doses of Eylea or Lucentis as clinically indicated every 1 month; BCVA and SDOCT exam 4-6 weeks after the third injection | Research Office, Health Bureau; Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Health and Medical Research Fund | Neovascular age-related macular degeneration, polypoidal choroidal vasculopathy | | | | |
NCT05297292: A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD |
|
|
| Recruiting | 2/3 | 433 | RoW | MW02, Lucentis, ranibizumab | Mabwell (Shanghai) Bioscience Co., Ltd. | Wet Age-related Macular Degeneration | 05/23 | 06/24 | | |
ChiCTR2100042994: A multicenter, randomized, double-blind, positive-controlled, seamless design Phase II/III clinical study to evaluate the efficacy and safety of recombinant anti-VEGF humanized monoclonal antibody injection (code MW02) in the treatment of neovascular (wet) age-related macular degeneration (nAMD) |
|
|
| Recruiting | 2/3 | 433 | | injection of MW02 every 4 week ;The first 3 injections, Q4w, followed by Q8w, were injected with MW02 ;injection of lucentis every 4 week | Mabwell (Shanghai) Bioscience Co., Ltd.; Level of the institution：, pay one's own expenses | Wet age-related macular degeneration | | | | |
BRUNELLO, NCT06571045: A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME |
|
|
| Recruiting | 2/3 | 960 | Europe, US, RoW | Ranibizumab, Lucentis, EYE103, Restoret | EyeBiotech Ltd. | Diabetic Macular Edema (DME) | 12/27 | 12/27 | | |
